amerithroid: consistent potency and quality, refill after refill
every batch is tested against USP standards ensuring quality of the active ingredient and finished product—so the dose you prescribe is the dose your patient receives.
quality control
![](data:image/svg+xml,<svg display="block" id="1410198439" role="presentation" viewBox="0 0 333 329" xmlns="http://www.w3.org/2000/svg"><g fill="transparent" height="236.01786053510875px" id="TY86WLVUZ" transform="translate(38.971 46.982)" width="256.0292756346907px"><path d="M 0.133 200.072 L 0.133 203.599 C 43.636 122.48 125.522 73.103 125.522 73.103 C 19.965 155.505 24.124 227.646 24.124 227.646 C 135.118 288.245 256.029 0 256.029 0 C -14.261 47.132 0.133 200.072 0.133 200.072" fill="rgb(51, 51, 153)" height="236.01786053510878px" id="QSNgwbaET" transform="translate(0 0)" width="256.0292756346907px"/></g></svg>)
Sourced and made in the United States within a routinely FDA-inspected facility
Distinct Oliva leaf imprint on every tablet for visible quality control
Mirrors standard dosing conventions with clear tablet markings
individualized dosing¹
Tablets not actual size.
The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. Thyroid hormones are given orally.
strength (mg)
strength (grain)
15 mg
1/4 grain
30 mg
1/2 grain
60 mg
1 grain
90 mg
1 1/2 grain
120 mg
2 grain
180 mg
3 grain
240 mg
4 grain
300 mg
5 grain
prescribing amerithroid
oliva NDC #
Cardinal Item #
Cencora Item #
McKesson Item #
Morris & Dickson Item #
82685-
341-01
6149108
Pending
3156676
989004
82685-
342-01
6149116
Pending
3156619
989954
82685-
343-01
6149124
Pending
3156684
990028
82685-
344-01
6149132
Pending
3156692
990093
82685-
345-01
6149140
Pending
3156700
990119
82685-
346-01
6149157
Pending
3156718
990168
82685-
347-01
6149165
Pending
3156742
990283
82685-
348-01
6149173
Pending
3156775
990309
individualized dosing¹
Tablets not actual size.
The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. Thyroid hormones are given orally.
15 mg
1/4 grain
Oliva NDC #
82685- 341-01
Cardinal Item #
6149108
Cencora Item #
Pending
McKesson Item #
3156676
Morris & Dickson Item #
989004
60 mg
1 grain
Oliva NDC #
82685- 343-01
Cardinal Item #
6149124
Cencora Item #
Pending
McKesson Item #
3156684
Morris & Dickson Item #
990028
120 mg
2 grain
Oliva NDC #
82685- 345-01
Cardinal Item #
6149140
Cencora Item #
Pending
McKesson Item #
3156700
Morris & Dickson Item #
990119
240 mg
4 grain
Oliva NDC #
82685- 347-01
Cardinal Item #
6149165
Cencora Item #
Pending
McKesson Item #
3156742
Morris & Dickson Item #
990283
30 mg
1/2 grain
Oliva NDC #
82685- 342-01
Cardinal Item #
6149116
Cencora Item #
Pending
McKesson Item #
3156619
Morris & Dickson Item #
989954
90 mg
1 1/2 grain
Oliva NDC #
82685- 344-01
Cardinal Item #
6149132
Cencora Item #
Pending
McKesson Item #
3156692
Morris & Dickson Item #
990093
180 mg
3 grain
Oliva NDC #
82685- 346-01
Cardinal Item #
6149157
Cencora Item #
Pending
McKesson Item #
3156718
Morris & Dickson Item #
990168
300 mg
5 grain
Oliva NDC #
82685- 348-01
Cardinal Item #
6149173
Cencora Item #
Pending
McKesson Item #
3156775
Morris & Dickson Item #
990309
individualized dosing¹
Tablets not actual size.
The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. Thyroid hormones are given orally.
15 mg
1/4 grain
Oliva NDC #
82685- 341-01
Cardinal Item #
6149108
Cencora Item #
Pending
McKesson Item #
3156676
Morris & Dickson Item #
989004
30 mg
1/2 grain
Oliva NDC #
82685- 342-01
Cardinal Item #
6149116
Cencora Item #
Pending
McKesson Item #
3156619
Morris & Dickson Item #
989954
60 mg
1 grain
Oliva NDC #
82685- 343-01
Cardinal Item #
6149124
Cencora Item #
Pending
McKesson Item #
3156684
Morris & Dickson Item #
990028
90 mg
1 1/2 grain
Oliva NDC #
82685- 344-01
Cardinal Item #
6149132
Cencora Item #
Pending
McKesson Item #
3156692
Morris & Dickson Item #
990093
120 mg
2 grain
Oliva NDC #
82685- 345-01
Cardinal Item #
6149140
Cencora Item #
Pending
McKesson Item #
3156700
Morris & Dickson Item #
990119
180 mg
3 grain
Oliva NDC #
82685- 346-01
Cardinal Item #
6149157
Cencora Item #
Pending
McKesson Item #
3156718
Morris & Dickson Item #
990168
240 mg
4 grain
Oliva NDC #
82685- 347-01
Cardinal Item #
6149165
Cencora Item #
Pending
McKesson Item #
3156742
Morris & Dickson Item #
990283
300 mg
5 grain
Oliva NDC #
82685- 348-01
Cardinal Item #
6149173
Cencora Item #
Pending
McKesson Item #
3156775
Morris & Dickson Item #
990309
To help ensure your patients receive amerithroid in the correct dose, as prescribed, write “dispense as written” (DAW 1) on the prescription.*
* Dispense as written or equivalent language in your state. Pharmacy rules and local laws may vary.
References
References: 1. Amerithroid Thyroid Tablets, USP [package insert]. Ridgewood, NJ: Oliva Therapeutics, LLC; 02/2025.
References
References: 1. Amerithroid Thyroid Tablets, USP [package insert]. Ridgewood, NJ: Oliva Therapeutics, LLC; 02/2025.
References
References: 1. Amerithroid Thyroid Tablets, USP [package insert]. Ridgewood, NJ: Oliva Therapeutics, LLC; 02/2025.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.